Raptor Pharmaceutical Obtains Tissue Fibrotic Disease Intellectual Property Related to Cysteamine

Raptor Pharmaceutical acquired exclusive worldwide rights to intellectual property related to cysteamine and related compounds in the potential treatment of tissue fibrosis from the Seattle Children’s Research Institute.
NASDAQ